Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Acrivastine
Accession Number
DB09488
Type
Small Molecule
Groups
Approved
Description

Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia.

Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D.

Structure
Thumb
Synonyms
  • (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}acrylic acid
  • acrivastina
  • Acrivastine
External IDs
BW 825C / BW A825C / BW-825C / BW-A825C / BW825C / BWA825C
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Semprex DAcrivastine (8 mg/1) + Pseudoephedrine hydrochloride (60 mg/1)CapsuleOralEndo Pharmaceuticals, Inc.2012-01-26Not applicableUs
Semprex-DAcrivastine (8 mg/1) + Pseudoephedrine hydrochloride (60 mg/1)CapsuleOralUcb Inc2008-05-27Not applicableUs
Categories
UNII
A20F9XAI7W
CAS number
87848-99-5
Weight
Average: 348.4382
Monoisotopic: 348.183778022
Chemical Formula
C22H24N2O2
InChI Key
PWACSDKDOHSSQD-IUTFFREVSA-N
InChI
InChI=1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
IUPAC Name
(2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
SMILES
[H]\C(CN1CCCC1)=C(\C1=CC=C(C)C=C1)C1=CC=CC(=N1)C(\[H])=C(/[H])C(O)=O

Pharmacology

Indication

For the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion.

Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AHistamine H1 receptor
antagonist
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Acrivastine was absorbed rapidly from the combination capsule following oral administration and was as bioavailable as a solution of acrivastine. After administration of SEMPREX-D Capsules, maximum plasma acrivastine concentrations were achieved at 1.14 ± 0.23 hour.

Volume of distribution

0.46 ± 0.05 L/kg

Protein binding

Acrivastine binding to human plasma proteins was 50 ± 2.0%.

Metabolism
Not Available
Route of elimination

A mass balance study in 7 healthy volunteers showed that acrivastine is primarily eliminated by the kidneys. Over a 72-hour collection period, about 84% of the administered total radioactivity was recovered in urine and about 13% in feces, for a combined recovery of about 97%.

Half life

The mean terminal half-life for acrivastine was 1.9 ± 0.3 hours following single oral doses and increased to 3.5 ± 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 ± 1.4 hours.

Clearance

2.9 ± 0.7 mL/min/kg

Toxicity
Not Available
Affected organisms
Not Available
Pathways
PathwayCategory
Acrivastine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Acrivastine.
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Acrivastine.
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Acrivastine.
AbacavirAbacavir may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AbexinostatThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Abexinostat.
AcarboseAcarbose may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcebutololThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Acebutolol.
AceclofenacAceclofenac may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AceprometazineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Aceprometazine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0240231
KEGG Drug
D02760
PubChem Compound
5284514
PubChem Substance
310265225
ChemSpider
4447574
ChEBI
83168
ChEMBL
CHEMBL1224
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Acrivastine
ATC Codes
R06AX18 — Acrivastine
FDA label
Download (2.43 MB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00994 mg/mLALOGPS
logP4.29ALOGPS
logP1.71ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)3.68ChemAxon
pKa (Strongest Basic)8.63ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area53.43 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity115.08 m3·mol-1ChemAxon
Polarizability39.09 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Styrenes
Direct Parent
Styrenes
Alternative Parents
Toluenes / Pyridines and derivatives / N-alkylpyrrolidines / Heteroaromatic compounds / Trialkylamines / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Styrene / Toluene / Pyridine / N-alkylpyrrolidine / Pyrrolidine / Heteroaromatic compound / Amino acid or derivatives / Tertiary amine / Tertiary aliphatic amine / Amino acid
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyridines, alpha,beta-unsaturated monocarboxylic acid, olefinic compound, N-alkylpyrrolidine (CHEBI:83168)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da

Drug created on November 30, 2015 12:10 / Updated on November 02, 2019 02:38